Suppliers / Qidong Dongyue Pharmaceutical

Qidong Dongyue Pharmaceutical

China Updated 9 July 2026

Qidong Dongyue Pharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files and 2 valid CEPs across a filed portfolio of 3 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 16 August 2024 as NAI.

3
active US DMFs
2
valid CEPs
3
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 16 August 2024 NAI US FDA
  • 31 March 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3003969382
Qidong City, China Not on file
Qidong, China Not on file

What they file, and where

Molecule Regulators Docs
Diphenhydramine EDQM, US FDA 2
Dipyridamole EDQM, US FDA 2
Dextromethorphan US FDA 1

Also appears on these molecule pages

Dextromethorphan API Diphenhydramine API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Qidong Dongyue Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 16 August 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates